Eric A. Hughes - 03 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Executive Vice President, Global R&D and Chief Medical Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes
Issuer symbol
TEVA
Transactions as of
03 Mar 2026
Net transactions value
-$2,613,450
Form type
4
Filing time
05 Mar 2026, 16:01:11 UTC
Previous filing
29 Jan 2026
Next filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hughes Eric A Executive Vice President, Global R&D and Chief Medical Officer C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes 05 Mar 2026 0001938678

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +24,900 24,900 03 Mar 2026 Direct F1, F2
transaction TEVA Ordinary Shares Sale $390,811 -12,077 -49% $32.36 12,823 03 Mar 2026 Direct F1, F3, F4, F5
transaction TEVA Ordinary Shares Options Exercise +141,478 +1103% 154,301 03 Mar 2026 Direct F1, F2
transaction TEVA Ordinary Shares Sale $2,222,640 -68,685 -45% $32.36 85,616 03 Mar 2026 Direct F1, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise -24,900 -50% $0.000000* 24,901 03 Mar 2026 Ordinary Shares 24,900 Direct F1, F2, F6
transaction TEVA Restricted Share Units Options Exercise -141,478 -100% $0.000000* 0 03 Mar 2026 Ordinary Shares 141,478 Direct F1, F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
F4 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 Restricted share units were granted on March 3, 2023, with 24,900 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.
F7 Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer